Document is current
Any future updates will be listed below
-
Authors
Dang, Fabin http://orcid.org/0000-0002-1954-8231
Nie, Li
Zhou, Jin http://orcid.org/0000-0001-8121-4198
Shimizu, Kouhei http://orcid.org/0000-0001-9523-4296
Chu, Chen http://orcid.org/0000-0001-8084-0867
Wu, Zhong
Fassl, Anne
Ke, Shizhong
Wang, Yuangao
Zhang, Jinfang http://orcid.org/0000-0001-8487-6007
Zhang, Tao
Tu, Zhenbo http://orcid.org/0000-0002-3720-7844
Inuzuka, Hiroyuki
Sicinski, Piotr http://orcid.org/0000-0002-8859-5234
Bass, Adam J. http://orcid.org/0000-0002-8193-4758
Wei, Wenyi http://orcid.org/0000-0003-0512-3811
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K99CA263194, CA202634, P50 CA168504, P01 CA250959, P01CA098101, CA229307, R35CA253027, CA177910)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 5 February 2021
Accepted: 23 August 2021
First Online: 10 September 2021
Competing interests
: P.S. has been a consultant at Novartis, Genovis, Guidepoint, The Planning Shop, ORIC Pharmaceuticals, Syros, and Exo Therapeutics; his laboratory receives research funding from Novartis. W.W. is a co-founder and consultant for the ReKindle Therapeutics. A.J.B. received funding from Merck, Bayer, Novartis, and is an advisor to Earli and Helix Nano and a co-founder of Signet Therapeutics. Other authors declare no competing interests.
